The administration of serum samples of patients with PsA with neutralizing PGRN Abs, and thus with lower PGRN levels, protected the WEHI-S and HT-1080 cells from the cytotoxic effects of TNF-α far less than serum samples from patients with PsA without PGRN Abs, patients with PsC or healthy controls. Here, GRN is linked to pancreatic serous cystadenoma.